Latest revenue
$5.2M
as of 2024-09-30
Latest net income
$-535.0K
as of 2024-09-30
Net margin
-10.3%
as of 2024-09-30
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $14.7M
- Enterprise value
- $14.7M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $2.50
- 52-wk low
- $1.33
- Beta
- —
- Shares out
- 6.1M
5-year trend
What this company does
Item 1. Business General Psychemedics Corporation is a Delaware corporation organized on September 24, 1986. All of our physical assets are located within the United States. We provide testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples. Our testing methods utilize a patented technology that digests the hair and releases drugs and substances trapped in the hair without destroying the drugs. This is fundamental to the entire process because the patented method gets virtually 100% of the drug out of the hair. Extracting the drug is an essential prerequisite to measuring it. We then perform a proprietary custom-designed patented…
AI summary unavailable — showing raw filing excerpt
Generated from PMDI's filing dated 2025-03-24
Key risks
Item 1A. Risk Factors In addition to other information contained in this Form 10-K, the following risk factors should be carefully considered in evaluating Psychemedics Corporation and our business because such factors could have a significant impact on our business, operating results, and financial condition. Additional risks not presently known to us, or that we presently deem immaterial, may also negatively impact us. These risk factors could cause actual results to differ materially from those projected in any forward-looking statements. Risks Related to Our Business and Operations Companies may develop products that compete with our products and some of these companies may be larger…
AI summary unavailable — showing raw filing excerpt
Generated from PMDI's filing dated 2025-03-24
Profitability
Gross margin
36.1%
5.2%Operating margin
-9.6%
27.2%Net margin
-9.5%
49.7%Return on equity
-36.3%
41.7%Return on assets
-22.4%
33.6%Leverage
Debt / equity
0.62×
26.7%Long-term debt / equity
0.01×
Debt / assets
38.3%
16.4%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2024 2024-12-31 | $4.4M | — | $189.0K | — | 4.3% |
Q3 2024 2024-09-30 | $5.2M | -9.3% | $-535.0K | +74.5% | -10.3% |
Q2 2024 2024-06-30 | $4.7M | -14.6% | $-827.0K | -13.9% | -17.5% |
Q1 2024 2024-03-31 | $5.4M | — | $-688.0K | — | -12.8% |
Q3 2023 2023-09-30 | $5.7M | — | $-2.1M | — | -36.8% |
Q2 2023 2023-06-30 | $5.5M | — | $-726.0K | — | -13.1% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Medical Laboratories · SIC 8071
Your notes
Keep private notes on PMDI — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for PMDI in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns PMDI
Institutional value
$441.7K
Total shares held
276.0K
Distinct holders
1
+0 vs prior
As of
2025-12-31
Prior: 2025-09-30
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | 22NW, LP | 276.0K | $441.7K | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once PMDI's latest filing finishes processing.